Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.34 |
| ▸ | CCR5 | P51681 | 1/20 | 0.34 |
| ▸ | CCR8 | P51685 | 1/20 | 0.34 |
| ▸ | ATR | Q13535 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ASPH | Q12797 | 1/20 | 0.32 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1699332 | 0.83 | ATR (0.36) | ATRLMNASMN1; SMN2KDM4EASPH | |
| SCHEMBL1350020 | 0.77 | ATR (0.34) | ATRLMNASMN1; SMN2KDM4EASPH | |
| SCHEMBL23854582 | 0.75 | KDM5A (0.35) | ATRKDM4EASPHKDM8 | |
| SCHEMBL1160881 | 0.72 | MEN1 (0.33) | ATRCNR2 | |
| SCHEMBL17601395 | 0.72 | ERN1 (0.39) | — | |
| SCHEMBL4072497 | 0.72 | KDM4C (0.34) | LMNAKDM4E | |
| SCHEMBL14909183 | 0.72 | KDM4E (0.39) | ATRLMNASMN1; SMN2KDM4EASPH | |
| SCHEMBL1353016 | 0.72 | TRIM24 (0.41) | LMNASMN1; SMN2KDM4E | |
| SCHEMBL1119415 | 0.72 | ALDH1A1 (0.32) | LMNAKDM4E | |
| SCHEMBL238763 | 0.71 | SMN1; SMN2 (0.46) | LMNASMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120004240-A1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME LLC | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004240-A1 | INHIBITORS OF AKT ACTIVITY | PIK3CD, PIK3CA, PIK3R5 | CCR1 4833/4885CCR5 3560/4885CCR8 4845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.